Dr. Robert E. Mutterperl, DO
Internal Medicine (Internal Medicine Physician)
6296 E Grant Rd Ste 140
Tucson, AZ 85712
Who else practices at this address →
Pima County includes primary care (34% of residents) and dental (4% of residents) and mental health (14% of residents) shortage areas. About shortage areas
At a glance
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
AZ license 3369
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 160 | 15 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 56 | 12 |
| Hospital discharge day management, 30 minutes or less | 17 | 14 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 16 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Tucson, AZ | 24 |
| Furosemide Other prescribers in Tucson, AZ | 22 |
| Metoprolol Tartrate Other prescribers in Tucson, AZ | 14 |
| Atorvastatin Calcium Other prescribers in Tucson, AZ | 11 |
| Levetiracetam Other prescribers in Tucson, AZ | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 3 companies. The companies reported $496,376 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age
ModernaTX, Inc. · Completed · NCT05127434 - A Phase IIb Randomized Double blind Placebo controlled and Open label Active Comparator Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus
AstraZeneca Pharmaceuticals LP - A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate …
AstraZeneca Pharmaceuticals LP - A phase III,randomised,double blind,placebo controlled,event driven study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outco…
AstraZeneca Pharmaceuticals LP - A phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd …
AstraZeneca Pharmaceuticals LP - Double blind study to determine efficacy of ASO Factor B in IgAN
Hoffmann-la Roche Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.